Related Experiment Video
Updated: Aug 20, 2025
08:36
Measuring Dengue Virus RNA in the Culture Supernatant of Infected Cells by Real-time Quantitative Polymerase Chain Reaction
Published on: November 1, 2018
32.0K
Biologics for dengue prevention: up-to-date.
Adam T Waickman1, Krista Newell1, Timothy P Endy1
1Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY USA.
Expert Opinion on Biological Therapy
|November 23, 2022
Summary
Dengue is a growing global health threat. This review covers dengue vaccine and antiviral progress, alongside new human infection models to accelerate product development for better dengue control.
Area of Science:
- * Virology and Immunology
- * Epidemiology and Public Health
- * Vaccinology and Pharmaceutical Development
Background:
- * Dengue virus (DENV) infections pose a significant and increasing global health challenge.
- * Sequential infections with different DENV serotypes heighten the risk of severe dengue disease.
- * Current dengue treatment is supportive; no licensed antivirals or immunotherapeutics exist.
Approach:
- * This review examines the current landscape of dengue vaccine and antiviral drug development.
- * It also discusses advancements in controlled human infection models to aid product development.
- * Focus is placed on strategies to overcome challenges in dengue prevention and treatment.
Key Points:
- * A single dengue vaccine is licensed, with two more in late-stage clinical trials.
- * Dengvaxia® adoption is limited due to safety concerns in specific populations.
- * Development of safe and effective antivirals is crucial for unvaccinated individuals and vaccine failures.
Conclusions:
- * There is a critical need for a safe, broadly protective tetravalent dengue vaccine for diverse populations.
- * Development of effective antivirals is essential to manage dengue in various clinical scenarios.
- * Innovations in research models are vital to expedite the availability of new dengue interventions.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
00:42Cross-reactivity
31.4K
Overview
31.4K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
834
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
834